Adocia is now integrated into the EnterNext Tech 40 Index

- Adocia is now listed amongst the best performing high tech companies of Euronext exchange.

Lyon, April, 29th, 2015 – Adocia (Euronext Paris: FR0011184241 – ADOC) announces today having been awarded the EnterNext Tech 40 Label and will be integrated into the Tech 40 index which will be launched on May 4, 2015.

EnterNext, a Euronext subsidiary, assigns this recognition each year to 40 technologically innovative European companies listed on Euronext exchange. This distinction is based on criteria related to business, financial and stock market performance.

Adocia has been selected from amongst 320 European listed companies to be integrated into this new index. As such, Adocia will enjoy a year-long promotion program and special assistance to enhance its visibility, especially via international roadshows.

About Adocia

To be a global leader in the innovative delivery of insulins and therapeutic proteins

Adocia is a clinical stage biotechnology company that specializes in the development of innovative formulations of already approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia’s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of its new formulation of insulin lispro, BioChaperone Lispro, previously tested successfully in two phase Ib/IIa studies.

Adocia will continue to develop its fast-acting human insulin formulation internally. Two clinical studies are planned over 2015, a post-meal glucose control study with HinsBet U100 and a PK/PD study with HinsBet U500. Adocia is also actively continuing the development of its BioChaperone Combo, a unique combination of insulin Glargine, the gold-standard of basal insulin and insulin Lispro, a fast-acting insulin analog. A dose-response clinical study (Phase IIa) is scheduled for the second quarter of 2015.

In addition, Adocia launched a phase III clinical study in India on its product based on PDGF-BB for treatment of the diabetic foot ulcer (BioChaperone PDGF-BB) in August 2014.
Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). Adocia is engaged in collaborative programs with two major pharmaceutical companies in this field.

**Fighting cancer with targeted treatments**

DriveIn® is a nanotechnology which is intended to significantly improve delivery of active compounds into cancer cells. This new proprietary platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

« Innovative medicine for everyone, everywhere »

Adocia’s therapeutic innovations aim to provide solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

Adocia is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and is included in the Next Biotech index.

American Depositary Receipts representing Adocia common stock are traded on the US OTC market under the ticker symbol ADOCY.

For more information, visit: [www.adocia.com](http://www.adocia.com)

---

**For more information please contact:**

<table>
<thead>
<tr>
<th>Adocia</th>
<th>Adocia Press Relations</th>
</tr>
</thead>
</table>
| Gérard Soula  
Chairman and CEO of Adocia  
contactinvestisseurs@adocia.com  
Tel.: +33 4 72 610 610 | ALIZE RP  
Caroline Carmagnol  
caroline@alizerp.com  
adocia@alizerp.com  
Tel.: + 33 1 44 54 36 61 |

---

**Disclaimer**

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the anticipated events in such forward-looking statements will occur. Forward-looking statements are subject to numerous risks and uncertainties including the risks set forth in the document titled “Risk Factors”, which is available on the Adocia’s website (www.Adocia.com section « A LA UNE/ SPOTLIGHT ») and, in particular to the uncertainties linked to research and development, future clinical data and analysis, and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.

This announcement is for information purposes only and does not, and shall not, in any circumstances, constitute a public offering by Adocia nor a solicitation of an offer to subscribe for securities in any jurisdiction, including France. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.